Oncology Companion Diagnostic Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035

The global oncology companion diagnostic market is witnessing notable growth as precision medicine becomes more deeply embedded in cancer treatment pathways. The market is valued at USD 5.68 billion in 2025 and is projected to reach USD 12.84 billion by 2035, reflecting a CAGR of 8.50% during the forecast period from 2026 to 2035. This expansion highlights the rising reliance on diagnostics that can identify the most appropriate therapies for individual cancer patients based on molecular and biomarker characteristics.

A key driver of this market is the increasing use of streamlined regulatory frameworks that help accelerate the introduction of new diagnostic technologies into clinical settings. In parallel, the growing adoption of liquid biopsy is widening the scope of oncology companion diagnostics by enabling less invasive biomarker assessment and supporting faster, more accessible cancer management.

Noteworthy Market Developments

The oncology companion diagnostic market is defined by a competitive environment in which large diagnostic companies operate alongside highly agile genomic innovators. Roche Diagnostics has built a strong leadership position through a broad ecosystem that includes tissue-based immunohistochemistry through the Ventana platform and comprehensive genomic profiling through Foundation Medicine. This integrated approach has strengthened its role across multiple segments of oncology testing.

Agilent Technologies also holds a significant position, particularly in the PharmDx category, where it works closely with pharmaceutical companies to co-develop companion diagnostics aligned with major immunotherapy products. These collaborative models are strengthening the linkage between therapeutic development and diagnostic commercialization, reinforcing the strategic importance of companion diagnostics in oncology pipelines.

Core Growth Drivers

Hospitals and cancer centers are increasingly shifting from sending samples to centralized reference laboratories toward deploying kitted next-generation sequencing solutions in-house. This transition is driven by the need to reduce turnaround time, improve operational control, and support faster treatment decisions. By performing testing on-site, institutions can move from multi-week reporting cycles to result delivery within a few days, which is particularly important in oncology settings where therapeutic timing can strongly influence outcomes.

Emerging Opportunity Trends

Artificial Intelligence is becoming a major force in the oncology companion diagnostic market, especially in pathology. Historically, biomarker scoring has depended heavily on manual interpretation, creating variability in results. AI-driven pathology tools are changing this model by helping pathologists achieve more accurate, consistent, and reproducible biomarker assessment. This trend is expected to strengthen the clinical reliability of companion diagnostics and improve confidence in treatment selection decisions.

Barriers to Optimization

The oncology companion diagnostic market faces substantial regulatory challenges because approval requirements remain strict, fragmented, and region-specific. Regulatory agencies such as the FDA and EMA maintain different standards, timelines, and documentation expectations. This lack of harmonization increases the burden on manufacturers, extends review periods, and raises commercialization costs, ultimately slowing the pace at which new companion diagnostic technologies can reach global markets.

Detailed Market Segmentation

By Disease Type, Non-small Cell Lung Cancer leads the oncology companion diagnostic market because it accounts for nearly 87% of lung cancer cases worldwide. Its dominance is reinforced by the growing complexity of treatment pathways, where multiple targeted therapies require precise molecular testing to identify actionable mutations and optimize clinical decision-making.

By End-use, hospitals hold the leading position as the market increasingly moves toward a patient-centric care model. Hospitals are able to integrate diagnosis, biomarker testing, and treatment planning within one setting, which improves efficiency and enhances the patient experience while supporting faster therapeutic action.

By Technology, Next-Generation Sequencing commands a 38% share of market revenue in 2025 and has established itself as the leading precision oncology technology. Its strength lies in its ability to provide comprehensive genomic profiling, which represents a significant advancement beyond single-biomarker PCR testing and enables broader molecular characterization of tumors.

Segment Breakdown

By Product & Services

• Product
• Software

By Technology

• Polymerase Chain Reaction (PCR)
• Next-generation Sequencing (NGS)
• Immunohistochemistry (IHC)
• In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH)
• Other Technologies

By Disease Type

• Breast Cancer
• Non-small Cell Lung Cancer
• Colorectal Cancer
• Leukemia
• Melanoma
• Prostate Cancer
• Others

By End-use

• Hospital
• Pathology/Diagnostic Laboratory
• Academic Medical Center

By Region

• North America
• The US
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia and New Zealand
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East and Africa
• Saudi Arabia
• South Africa
• UAE
• Rest of MEA
• South America
• Argentina
• Brazil
• Rest of South America

Geographical Breakdown

Asia Pacific is emerging as the most dynamic and fastest-growing region in the oncology companion diagnostic market, with projected growth ranging from 13.3% to 13.55% through 2030. This strong momentum is supported by the region’s large cancer patient population, improving healthcare capacity, and government-backed efforts to strengthen oncology care. China is a major contributor to this trend through the Healthy China 2030 initiative, which is accelerating the development of domestic next-generation sequencing platforms and AI-driven diagnostic technologies. These developments are positioning Asia Pacific as a major growth engine for the oncology companion diagnostic market.

Leading Market Participants

• Abbott Laboratories
• Agilent Technologies
• Bio-Rad Laboratories
• Biocartis
• Exact Sciences
• Genedrive
• Genomic Health
• Guardant Health
• Illumina
• Invivoscribe
• Myriad Genetics
• QIAGEN
• Roche Diagnostics
• Sysmex Corporation
• Thermo Fisher Scientific
• Other Prominent Players